Vitiligo May Be First Sign of Localized Scleroderma

BY HEIDI SPLETE
Senior Writer

CHICAGO — When facing a child with localized scleroderma, be wary if the scleroderma is linear, especially if it is on the face or on a limb where it crosses a joint, Dr. Amy Gilliam said at the annual meeting of the Society for Pediatric Dermatology.

However, not all young people initially present with the skin hardening and atrophy that characterizes scleroderma, explained Dr. Gilliam, a dermatologist at the University of California, San Francisco. Instead, these patients are often misdiagnosed with vitiligo for months or years before the correct diagnosis of juvenile localized scleroderma is made.

To better characterize localized scleroderma in children, Dr. Gilliam and her colleagues reviewed data from 127 patients younger than 21 years who were evaluated at UCSF. Dr. Gilliam’s research was supported in part by a grant from the Society for Pediatric Dermatology and the Dermatology Foundation, but she had no other financial disclosures.

“Something unique in our study is that we collected information on body surface area of involvement,” Dr. Gilliam said. “And we had a dermatology perspective rather than a rheumatology perspective.

“One of the interesting things that came out of our data was that the presenting sign in about 50% of the patients was some type of dyspigmentation, either hyper-, hypo- or depigmentation,” she said. Add the 19 patients who had what they called a “bruise,” and dyspigmentation was a presenting symptom in nearly two-thirds of the cases.

Another key finding was that patients whose scleroderma involved 9% or more of their total body surface area were significantly more likely to have extracutaneous symptoms—including arthralgias and orthopedic, pulmonary, and gastrointestinal problems—than were patients whose scleroderma involved less than 5% of their total body surface area. The significance was true in separate analyses of the 89 patients whose charts were reviewed retrospectively and the 38 patients who were studied prospectively and followed.

But neurologic problems were the notable exception in the patient population. “That sticks out like a sore thumb,” said Dr. Gilliam. Localized scleroderma on less than 5% of the body surface area was significantly more common in patients with nonfacial linear scleroderma, compared with those who had other forms of localized scleroderma (22% vs. 4%).

But body surface area alone is not enough to assess localized scleroderma, Dr. Gilliam emphasized. The patients to worry about are those with segmental or linear presentations and those with the characteristic pinkish-purple macules that indicate generalized morphea.

It’s important to think about location in cases of localized scleroderma, Dr. Gilliam added. In her study, gastrointestinal problems were significantly more common in patients with generalized morphea and in patients who had scleroderma on the trunk, compared with those who had scleroderma in other locations (21% vs. 5%).

But location isn’t everything: Pulmonary problems were significantly more common among patients with generalized morphea, but the presence or absence of localized scleroderma on the trunk was not significant.

Lastly, Dr. Gilliam did not find a significant association between positive levels of antinuclear antibodies and extracutaneous conditions, although she cited a separate study of 750 patients that did show a significant association (Arthritis Rheum. 2005;52:2873-81).

OXISTAT delivers:
- Broad approved tinea coverage with proven efficacy ≥80%
- Convenient once-daily application with no age limitations

OXISTAT CREAM may be used in pediatric patients for tinea corporis, tinea cruris, and tinea versicolor; however, these indications rarely occur in children below the age of 12.

OXISTAT CREAM and OXISTAT LOTION are contraindicated in individuals who have shown hypersensitivity to any of the medications’ components and are not for ophthalmic or intravaginal use. The most common adverse events with OXISTAT were pruritus and burning, which occurred in less than 2% of patients.

*OXISTAT CREAM is indicated for tinea versicolor due to Malassezia furfur.